Phytotherapics in COVID19: Why palmitoylethanolamide?

Area of Science:

• Nutritional Immunology
• Pharmacology
• Infectious Diseases

Background:

• Growing public and scientific interest in functional foods and nutraceuticals for COVID-19 prevention and treatment.
• Numerous phytotherapics have been proposed, necessitating scientific validation for their efficacy.
• Palmitoylethanolamide (PEA) has a historical background as an immunomodulatory agent for infections.

Purpose of the Study:

• To analyze the potential of palmitoylethanolamide (PEA) as a nutraceutical for COVID-19.
• To review existing evidence on PEA's anti-inflammatory and immunomodulatory properties in respiratory and infectious diseases.
• To explore the translation of PEA's properties to COVID-19 patient care.

Main Methods:

• Review of existing scientific literature on palmitoylethanolamide (PEA).
• Analysis of PEA's documented anti-inflammatory and immunomodulatory effects.
• Examination of historical data regarding PEA's use in infectious diseases.
• Consideration of a recent proof-of-concept study design for PEA in COVID-19 patients.

Main Results:

• Palmitoylethanolamide (PEA) has demonstrated immunomodulatory properties since the 1970s.
• PEA exhibits anti-inflammatory effects relevant to infectious and respiratory conditions.
• A proof-of-concept study is planned to evaluate ultramicronized PEA in COVID-19 patients.

Conclusions:

• Palmitoylethanolamide (PEA) shows promise as a nutraceutical intervention for COVID-19.
• Its established anti-inflammatory and immunomodulatory actions warrant further investigation in the context of this pandemic.
• Translating existing evidence on PEA to COVID-19 care requires rigorous scientific evaluation.